X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to focus on advancing and potentially accelerating the development of domvanalimab for the treatment of Metastatic Non-Small Cell Lung Cancer.
Lead Product(s): Zimberelimab,Domvanalimab,Carboplatin
Therapeutic Area: Oncology Product Name: GS-0122
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Gilead Sciences
Deal Size: $1,225.0 million Upfront Cash: $375.0 million
Deal Type: Collaboration January 29, 2024
Details:
AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor. It is being evaluated in phase 1 clinical trials in combination with zimberelimab and chemotherapy for the treatment of metastatic pancreatic cancer.
Lead Product(s): Quemliclustat,Zimberelimab,Paclitaxel
Therapeutic Area: Oncology Product Name: AB680
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
AB680 (quemliclustat) is an investigational small molecule CD73 inhibitor. It is under phase 1 clinical development for the treatment of in combination with chemotherapy with or without zimberelimab for treatment-naïve metastatic pancreatic cancer.
Lead Product(s): Quemliclustat,Zimberelimab,Paclitaxel
Therapeutic Area: Oncology Product Name: AB680
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The companies will enter into a clinical trial collaboration evaluating XL092 (zanzalintinib), a tyrosine kinase inhibitor, in combination with AB521 in patients with advanced solid tumors including clear cell renal cell carcinoma.
Lead Product(s): Encoberminogene Rezmadenovec,AB521
Therapeutic Area: Oncology Product Name: XL092
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Exelixis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 04, 2023
Details:
Under the terms of the expanded collaboration, Arcus will initiate research programs against up to four targets jointly selected by the parties that are applicable to inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,715.0 million Upfront Cash: $35.0 million
Deal Type: Expanded Collaboration May 15, 2023
Details:
Domvanalimab is an Fc-silent investigational monoclonal antibody that is designed to bind to TIGIT, a protein receptor on immune cells that acts as a brake on the immune response.
Lead Product(s): Etrumadenant,Zimberelimab
Therapeutic Area: Oncology Product Name: AB154
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
Initial pharmacokinetic /pharmacodynamic data for AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2α Inhibitor, in healthy volunteers, confirm its potential to have an improved clinical profile compared to that of only approved HIF-2a inhibitor.
Lead Product(s): AB521
Therapeutic Area: Oncology Product Name: AB521
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Preclinical research related to therapeutic opportunities to enhance anti-tumor immunity and new insights into the benet of dual A2a/A2b adenosine receptor antagonism, CD39 inhibition and HPK1 inhibition will be presented at the American Association for Cancer Research.
Lead Product(s): AB521
Therapeutic Area: Oncology Product Name: AB521
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Gilead exercised its options to anti-TIGIT molecules domvanalimab and AB308, as well as clinical candidates etrumadenant (dual adenosine A2a/A2b receptor antagonist) and quemliclustat (small molecule CD73 inhibitor).
Lead Product(s): Domvanalimab,Zimberelimab
Therapeutic Area: Oncology Product Name: AB154
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: $1,975.0 million Upfront Cash: $175.0 million
Deal Type: Expanded Collaboration December 21, 2021
Details:
Taiho exercised its option for anti-TIGIT antibodies domvanalimab (development code: AB154) and AB308 from Arcus Biosciences (“Arcus”), in Japan and certain other territories in Asia (excluding China).
Lead Product(s): Domvanalimab,Zimberelimab
Therapeutic Area: Oncology Product Name: AB154
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Taiho Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
